Abivax announces initial results from obefazimod combination mouse study

Abivax announced results of initial preclinical combination data of obefazimod combined with etrasimod in a mouse model of IBD. Preclinical evaluation of obefazimod combined with etrasimod, was conducted in the T-cell adoptive transfer mouse model. In this study, CD4+CD45high or CD4+CD45low cells were intraperitoneally injected to 6-week-old male mice. The mice were then orally treated for 55 days with obefazimod or etrasimod alone or with the combination of both compounds. The results showed that treatment with the combination improved the response on body weight protection and Disease Activity Index with a synergistic and statistically significant reduction of several cytokines in the blood compared to each drug alone.